Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial

On the one hand, a qualitative research carried out by clinical experts, the Pulmonary Hypertension Association Europe (PHA Europe) and the European Pulmonary Fibrosis …

Barcelona, February 6, 2024 - The pharmaceutical company Ferrer has been recognized for its leadership in corporate transparency, sustainability, and action against climate change by the …

Ferrer US is focused on the research and development of novel, proprietary products for the acute treatment of underserved medical needs, in the therapeutic areas of neurodegenerative …

Ferrer, the Liveable Planet pillar has an area of action dedicated to the protection of natural resources, including water. Currently, water scarcity affects more than 40% of the world's …

Ferrer's experience and knowledge make a difference in five treatment areas: pulmonary hypertension, the nervous system, pain, cardiometabolism, gastroenterology and dermatology. …

The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing …

Patient-Focused Initiatives Stay Informed About Patient-Led Efforts in PSP Awareness, Care and Research. Explore resources and activities spearheaded by patient associations to foster early …

Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study seeks to evaluate the safety …

With more than 60 years of experience, Ferrer boasts a consolidated trajectory oriented towards the improvement of health and quality of life of millions. Self-care products. The priority for …